Evidence map›Paper›PMID 35201316›Full record

ArticleBlood advances2022

CCR8 is a new therapeutic target in cutaneous T-cell lymphomas.

Jérôme Giustiniani, Gabor Dobos, Hélène Moins-Teisserenc, Tiago Eustaquio, Maxime Battistella, Nicolas Ortonne, Caroline Ram-Wolff, Jean-David Bouaziz, Anne Marie-Cardine, Samia Mourah and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Expansion of multiple CD4The Journal of allergy and clinical immunology · 2025
    Article
  4. Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 3 countries.

Jérôme GiustinianiINSERM, U955, Henri Mondor Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris Est Créteil, Créteil, France.
Gabor DobosDepartment of Dermatology, AP-HP, Saint Louis Hospital, Paris, France.
Hélène Moins-TeisserencInstitut de Recherche Saint-Louis, Université de Paris, Paris, France.
Tiago EustaquioINSERM, Unité Mixte de Recherche 1160, Paris, France.
Maxime BattistellaInstitut de Recherche Saint-Louis, Université de Paris, Paris, France.ORCID 0000-0002-7053-7431
Nicolas OrtonneINSERM, U955, Henri Mondor Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris Est Créteil, Créteil, France.ORCID 0000-0003-0111-7422
Caroline Ram-WolffDepartment of Dermatology, AP-HP, Saint Louis Hospital, Paris, France.
Jean-David BouazizDepartment of Dermatology, AP-HP, Saint Louis Hospital, Paris, France.
Anne Marie-CardineInstitut de Recherche Saint-Louis, Université de Paris, Paris, France.
Samia MourahInstitut de Recherche Saint-Louis, Université de Paris, Paris, France.
Martine BagotDepartment of Dermatology, AP-HP, Saint Louis Hospital, Paris, France.
Thomas S KupperDepartment of Dermatology, Dana Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA.
Rachael A ClarkDepartment of Dermatology, Dana Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA.
Armand BensussanInstitut de Recherche Saint-Louis, Université de Paris, Paris, France.ORCID 0000-0002-0409-2497
Adèle de MassonDepartment of Dermatology, AP-HP, Saint Louis Hospital, Paris, France.ORCID 0000-0001-7828-6211
Inserm · FRHarvard University · USAssistance Publique – Hôpitaux de Paris · FR

Funding

The Next Generation Immunoanalysis CoreP30AR069625 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI CLARK, RACHAEL ANN · 2016 to 2025
$8.8M
DERMATOLOGY TRAINING GRANTT32AR007098 · NIAMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI THOMAS S. KUPPER · 1986 to 2026
$8.1M
Skin Homing T CellsR01AR065807 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI KUPPER, THOMAS S. · 2013 to 2022
$6.3M
Transforming the diagnosis and care of patients with CTCL using TCR sequencingR01CA203721 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI CLARK, RACHAEL ANN, KUPPER, THOMAS S. · 2016 to 2020
$3.4M
Optimizing pre-analytic sample handling for high throughput TCR sequencing in cutaneous T cell lymphomaU01CA253190 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI CLARK, RACHAEL ANN · 2020 to 2024
$2.1M
Reversing immune evasion and enhancing immune detection with topical resiquimodR01AR074797 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI CLARK, RACHAEL ANN, ROOK, ALAIN H · 2018 to 2021
$1.9M
CTCL immunobiology: lessons from alemtuzumabR01AR063962 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI CLARK, RACHAEL ANN · 2013 to 2017
$1.8M
NCI NIH HHS R01 CA203721NCI NIH HHS U01 CA253190NIAMS NIH HHS P30 AR069625NIAMS NIH HHS R01 AR063962NIAMS NIH HHS R01 AR065807NIAMS NIH HHS R01 AR074797NIAMS NIH HHS T32 AR007098
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Lymphoma, T-Cell, CutaneousSkin NeoplasmsHumansReceptors, CCR8CCR8 protein, humanReceptors, CCR8

Identifiers

PMID35201316
PMCPMC9198911
OpenAlexW4214514582

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.